Christina Marie Coughlin

Title: Christina Marie Coughlin: Innovator in Cancer Research

Introduction

Christina Marie Coughlin is a notable inventor based in Berwyn, PA (US). She has made significant contributions to the field of cancer research, particularly in the area of tumor identification and treatment response prediction. Her innovative work has the potential to improve patient outcomes in oncology.

Latest Patents

Christina holds a patent for a groundbreaking invention titled "Cut-point in PTEN protein expression that accurately identifies tumors and is predictive of drug response to a pan-ErbB inhibitor." This patent describes a method for determining a cut-point in the quantitative measurement of PTEN protein expression. It accurately identifies tumors with two inactivated alleles of the PTEN gene. Patients with a normalized PTEN score of PTEN null are recommended to be treated with a pan-ErbB tyrosine kinase inhibitor. The normalized PTEN protein expression score is derived by comparing the tumor PTEN OD expression value with the non-malignant PTEN OD expression value. This innovation represents a significant advancement in personalized cancer therapy.

Career Highlights

Christina has had a distinguished career, working at Wyeth, where she has been able to apply her expertise in cancer research. Her work has been instrumental in developing new strategies for cancer treatment, focusing on the molecular mechanisms that underlie tumor behavior and drug response.

Collaborations

Throughout her career, Christina has collaborated with esteemed colleagues, including Jay Marshall Feingold and Daniel Stephen Johnston. These collaborations have fostered a rich exchange of ideas and have contributed to the advancement of cancer research.

Conclusion

Christina Marie Coughlin is a pioneering inventor whose work in cancer research has the potential to transform treatment approaches for patients. Her innovative patent on PTEN protein expression is a testament to her commitment to improving cancer care.